Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transforming growth factor-beta receptor-associated protein 1 (TGFBRAP1) is a cytoplasmic protein involved in the trafficking and fusion of early endosomes as a specific subunit of the CORVET (Class C core vacuole/endosome tethering) complex. It also binds to transforming growth factor-beta (TGF-beta) receptors and modulates TGF-beta/activin signaling, particularly by facilitating interactions with SMAD4 and influencing downstream signaling events. TGFBRAP1 is not a receptor, enzyme, or classical drug target but a tethering complex protein important for vesicle dynamics in the endocytic pathway, thus playing crucial roles in intracellular transport and signal transduction by regulating membrane fusion and trafficking. Mutations or dysregulation of TGFBRAP1 are implicated in some pathologies, including Long QT syndrome and neuroblastoma, though its direct role as a disease driver is not definitively characterized. There are no known drugs that directly target TGFBRAP1, nor is it established as a therapeutic target or clinical biomarker at this time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transforming growth factor-beta receptor-associated protein 1 (TGFBRAP1).